Safety of higher dosages of Viscum album L. in animals and humans - systematic review of immune changes and safety parameters

BMC Complementary and Alternative Medicine

Volumn 11, Issue , 2011, Pages

  Kienle, Gunver S ^a   Grugel, Renate ^a   Kiene, Helmut ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT MISTLETEO LECTIN; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT; VISCUM ALBUM LECTIN; ANTINEOPLASTIC AGENT; PLANT EXTRACT;

ALLERGIC REACTION; ARTICLE; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; DRY EYE; FATIGUE; FEVER; FLATULENCE; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INFECTION; INJECTION SITE REACTION; LASSITUDE; LIVER TOXICITY; LOOSE FECES; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PARAMETER; SIDE EFFECT; SYSTEMATIC REVIEW; TEMPERATURE; UNSPECIFIED SIDE EFFECT; VISCUM ALBUM; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG SCREENING; DRUG TOXICITY; IMMUNOLOGY; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; NEOPLASMS; PLANT EXTRACTS; VISCUM ALBUM;

EID: 80052025838     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-11-72     Document Type: Article

References (125)

1. Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 2005, 16:655-663. 10.1093/annonc/mdi110, 15699021.
2. Münstedt K, von Georgi R. Unkonventionelle Krebstherapien - Vergleich von Einstellungen und Kenntnissen bei Ärzten in Deutschland und Griechenland. Forsch Komplementmed 2005, 12:254-260.
3. Endo Y, Tsurugi K, Franz H. The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes. FEBS Lett 1988, 231:378-380. 10.1016/0014-5793(88)80853-6, 3360143.
4. Stirpe F, Sandvig K, Olsnes S, Pihl A. Action of viscumin, a toxic lectin from mistletoe, on cells in culture. J Biol Chem 1982, 257:13271-13277.
5. Stirpe F, Barbieri L, Battelli MG, Soria M, Lappi DA. Ribosome-inactivating proteins from plants: present status and future prospects. Biotechnology 1992, 10:405-412. 10.1038/nbt0492-405, 1368484.
6. Peumans WJ, Verhaert P, Pfüller U, Van Damme EJM. Isolation and partial characterization of a small chitin-binding lectin from mistletoe (Viscum album). FEBS Lett 1996, 396:261-265. 10.1016/0014-5793(96)01108-8, 8914999.
7. Klett CY, Anderer FA. Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from Viscum album extract. ArzneimForsch/DrugRes 1989, 39(II):1580-1585.
8. Mueller EA, Anderer FA. A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother 1990, 32:221-227. 10.1007/BF01741704, 2124513.
9. Orhan DD, Küpeli E, Yesilada E, Ergun F. Anti-inflammatory and antinociceptive activity of flavonoids isolated from VISCUM ALBUM ssp. ALBUM. Z Naturforsch [C] 2006, 61c:26-30.
10. Winkler K, Leneweit G, Schubert R. Characterization of membrane vesicles in plant extracts. Colloids Surf B Biointerfaces 2005, 45:57-65. 10.1016/j.colsurfb.2005.07.006, 16125916.
11. Jager S, Winkler K, Pfuller U, Scheffler A. Solubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L. Planta Med 2007, 73:157-162. 10.1055/s-2007-967106, 17415876.
12. Kienle GS, Kiene H. Die Mistel in der Onkologie - Fakten und konzeptionelle Grundlagen 2003, Stuttgart, New York: Schattauer Verlag.
13. Büssing A, . ed Mistletoe The Genus Viscum 2000, Amsterdam: Hardwood Academic Publishers, ed.
14. Eggenschwiler J, von BL, Stritt B, Pruntsch D, Ramos M, Urech K, Rist L, Simoes-Wust AP, Viviani A. Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata). BMC Complement Altern Med 2007, 7:14. 10.1186/1472-6882-7-14, 1878504, 17493268.
15. Büssing A, Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res 1999, 19:23-28.
16. Elsässer-Beile U, Lusebrink S, Grussenmeyer U, Wetterauer U, Schultze-Seemann W. Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes. Arzneim-Forsch/Drug Res 1998, 48(II):1185-1189.
17. Schumacher U, Feldhaus S, Mengs U. Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice. Cancer Lett 2000, 150:171-175. 10.1016/S0304-3835(99)00387-0, 10704739.
18. Elsässer-Beile U, Ruhnau T, Freudenberg M, Wetterauer U, Mengs U. Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer 2001, 91:998-1004. 10.1002/1097-0142(20010301)91:5<998::AID-CNCR1090>3.0.CO;2-Q, 11251952.
19. Schaffrath B, Mengs U, Schwarz T, Hilgers RD, Beuth J, Möckel B, Lentzen H, Gerstmayer B. Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice. Anticancer Res 2001, 21:3981-3987.
20. Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H, Twelves C, . European Organization for Research and Treatment of Cancer New Drug Development Group Phase I trial on intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol 2004, 15:1816-1824. 10.1093/annonc/mdh469, 15550588, European Organization for Research and Treatment of Cancer New Drug Development Group.
21. Schöffski P, Breidenbach I, Krauter J, Bolte O, Stadler M, Ganser A, Wilhelm-Ogunbiyi K, Lentzen H. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. Eur J Cancer 2005, 41:1431-1438. 10.1016/j.ejca.2005.03.019, 15913988.
22. Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H. Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: A study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). Eur J Cancer 2008, 44:1657-1662. 10.1016/j.ejca.2008.05.005, 18602257.
23. Kienle GS, Kiene H. Influence of Viscum Album L (European Mistletoe) Extracts on Quality of Life in Cancer Patients: A Systematic Review of Controlled Clinical Studies. Integr Cancer Ther 2010, 9:142-157. 10.1177/1534735410369673, 20483874.
24. Kienle GS, Glockmann A, Schink M, Kiene H. Viscum album L. extracts in breast and gynaecologic cancers: A systematic review of clinical and preclinical research. J Exp Clin Cancer Res 2009, 28:79. doi:10.1186/1756-9966-28-79, 2711058 , 19519890.
25. Kienle GS, Kiene H. Complementary Cancer Therapy: A Systematic Review of Prospective Clinical Trials on Anthroposophic Mistletoe Extracts. Eur J Med Res 2007, 12:103-119.
26. Kienle GS, Berrino F, Büssing A, Portalupi E, Rosenzweig S, Kiene H. Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 2003, 8:109-119.
27. Ostermann T, Raak C, Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer 2009, 9:451. 10.1186/1471-2407-9-451, 2804713, 20021637.
28. Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008, CD003297.
29. Lange-Lindberg AM, Velasco Garrido M, Busse R. Misteltherapie als begleitende Behandlung zur Reduktion der Toxizität der Chemotherapie maligner Erkrankungen. GMS Health Technol Assess 2006; 2:Doc18 (20060919) 2006,
30. Melzer J, Iten F, Hostanska K, Saller R. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementmed 2009, 16:217-226. 10.1159/000226249, 19729932.
31. Saller R, Kramer S, Iten F, Melzer J. Unerwünschte Wirkungen der Misteltherapie bei Tumorpatienten - Eine systematische Übersicht. Fortschritte in der Misteltherapie Aktueller Stand der Forschung und klinischen Anwendung 2005, 367-403. Essen, KVC Verlag, Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H.
32. Stein GM, Berg PA. Adverse effects during therapy with mistletoe extracts. Mistletoe The Genus Viscum 2000, 195-208. Amsterdam, Hardwood Academic Publishers, Büssing A.
33. Stein GM. Toxicology of mistletoe and their components. Mistletoe The Genus Viscum 2000, 183-194. Amsterdam, Hardwood Academic Publishers, Büssing A.
34. Kienle GS, Kiene H, Albonico HU. Anthroposophic Medicine: Effectiveness, Utility, Costs, Safety 2006, Stuttgart, New York: Schattauer Verlag.
35. Kienle GS, Kiene H. Verträglichkeit, Nebenwirkungen, Überempfindlichkeitsreaktionen, Toxizität. Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen 2003, 591-607. Stuttgart, New York, Schattauer Verlag.
36. Matthes H, Schad F, Schenk G. Viscum album in the therapy of primary inoperable hepatocellular carcinoma (HCC). (Abstract No. 755). Gastroenterology 2004, 126:A-101-A-102.
37. Matthes H, Buchwald D, Schad F, Schenk G. Treatment of inoperable pancreatic carcinoma with combined intratumoral mistletoe therapy. Gastroenterology 2005, 128:433. 10.1053/j.gastro.2004.11.065, 15685554.
38. Mabed M, El-Helw L, Sharma S. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer 2004, 90:65-69. 10.1038/sj.bjc.6601463, 2395314, 14710208.
39. Mahfouz MM, Ghaleb HA, Zawawy A, Scheffler A. Significant tumor reduction, improvement of pain and quality of life and normalization of sleeping patterns of cancer patients treated with a high dose of mistletoe. Ann Oncol 1998, 9:129.
40. Orange M, Fonseca M, Lace A, von Laue H-B, Geider S. Durable tumour responses following primary high dose induction with mistletoe extracts: Two case reports. Eur J Integr Med 2010, 2:63-69.
41. Burger AM, Mengs U, Schüler JB, Fiebig HH. Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro. ArzneimForsch/DrugRes 2001, 51:748-757.
42. Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J, Fiebig HH. Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. Anticancer Res 2005, 25:1969-1975.
43. Fritz P, Mürdter TE, Siegle I, Aulitzky W, Voelter W. Therapie mit Mistelextrakten in der Onkologie: eine Kontroverse ohne Ende?. Urologe 2001, 41:466-471.
44. Zuzak T, Rist L, Eggenschwiler J, Grotzer MA, Viviani A. Paediatric Medulloblastoma Cells are Susceptible to Viscum Album (Mistletoe) Preparations. Anticancer Res 2006, 26:3485-3492.
45. Thies A, Nugel D, Pfuller U, Moll I, Schumacher U. Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro. Toxicology 2005, 207:105-116. 10.1016/j.tox.2004.09.009, 15590126.
46. Kalden M. Klinische Erfahrungen mit Viscum album bei fortgeschrittenen Tumoren. Erfahrungsheilkunde 1994, 315-321.
47. Beuth J, Ko HL, Tunggal L, Buss G, Jeljaszewicz J, Steuer MK, Pulverer G. Immunaktive Wirkung von Mistellektin-1 in Abhängigkeit von der Dosierung. ArzneimForsch/DrugRes 1994, 44(II):1255-1258.
48. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche P, Ioannides CG, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6.
49. Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007, 7:32. 10.1186/1471-2288-7-32, 1933432, 17615054.
50. Descotes J. Drug-Induced Immune Diseases 2000, Amsterdam, New York, Oxford: Elsevier.
51. , . U.S.Department of Health, Human ServicesFood, Drug AdministrationCenter for Drug Evaluation, Research (CDER) Guidance for Industry. Immunotoxicology Evaluation of Investigational New Drugs 2002, U.S.Department of Health, Human ServicesFood, Drug AdministrationCenter for Drug Evaluation, Research (CDER).
52. Descotes J. An Introduction to Immunotoxicology 1999, London, Philadelphia: Taylor & Francis.
53. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol 2010, 125:195-203.
54. Dietert R. Immunotoxicity Testing: Methods and Protocols 2009, New York: Springer.
55. Thomas L. Labor und Diagnose 2007, Frankfurt am Main: Th-Books Verlagsgesellschaft.
56. Peter HH. Erworbene Immundefekte. Labor und Diagnose 2000, 751-759. Frankfurt am Main, TH-Books Verlagsgesellschaft, Thomas L, 5, Auflage.
57. Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs?. Immunol Lett 2007, 108:45-51. 10.1016/j.imlet.2006.10.009, 17129612.
58. Bedeutung der Bestimmung von Lymphozyten-Subpopulationen in der Umweltmedizin. Mitteilung der Kommission "Methoden und Qualitätssicherung in der Umweltmedizin". Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 2006, 49:468-484.
59. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte Trafficking and Regional Immunity. Adv Immunol 1999, 72:209-253.
60. Dhabhar FS. Enhancing versus Suppressive Effects of Stress on Immune Function: Implications for Immunoprotection versus Immunopathology. Allergy Asthma Clin Immunol 2008, 4:2-11. 10.1186/1710-1492-4-1-2, 2869337, 20525121.
61. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Immunotoxicity Studies for Human Pharmaceuticals, S8 2005, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
62. Musielski H, Rüger K. Verfahren zur quantitativen Bestimmung von Mistellektin I und Mistellektin II und/oder Mistellektin III in Mistelextrakten unter Verwendung monoklonaler Antikörper, die spezifisch mit Mistellektin reagieren. Grundlagen der Misteltherapie Aktueller Stand der Forschung und klinische Anwendung 1996, 95-104. Stuttgart, Hippokrates Verlag GmbH, Scheer R, Becker H, Berg PA.
63. Gorter RW, van Wely M, Reif M, Stoss M. Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern Ther Health Med 1999, 5:37-48.
64. van Wely M, Stoss M, Gorter RW. Toxicity of a standardized mistletoe extract in immunocomprised and healthy individuals. Am J Ther 1999, 6:37-43. 10.1097/00045391-199901000-00006, 10423645.
65. Lukyanova EM, Chernyshov VP, Omelchenko LI, Slukvin II, Pochinok TV, Antipkin JG, Voichenko IV, Heusser P, Schniedermann G. Die Behandlung immunsupprimierter Kinder nach dem Tschernobyl-Unfall mit Viscum album (Iscador): Klinische und immunologische Untersuchungen. Forsch Komplementmed 1994, 1:58-70.
66. Huber R, Klein R, Berg PA, Lüdtke R, Werner M. Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects. J Altern Complement Med 2002, 8:857-866. 10.1089/10755530260511847, 12614536.
67. Huber R, Klein R, Lüdtke R, Werner M. Häufigkeit grippaler Infekte bei Gesunden unter Gabe eines lektinreichen und eines lektinarmen Mistelpräparats im Rahmen einer randomisierten, doppelblinden, placebokontrollierten Studie. Forsch Komplementmed 2001, 8:354-358.
68. Büssing A, Rosenberger A, Stumpf C, Schietzel M. Entwicklung lymphozytärer Subpopulationen bei Tumorpatienten nach subkutaner Applikation von Mistelextrakten. Forsch Komplementmed 1999, 6:196-204.
69. Ghaleb HA. Report on Abnoba viscum - Multicentral clinical trial. 1997,
70. Chernyshov VP, Omelchenko LI, Heusser P, Slukvin II, Vodyanik MA, Galazyuk LV, Vykhovanets EV, Pochinok TV, Chernyshov AV, Gumenyuk ME, Schaefermeyer H, Schaefermeyer G. Immunomodulatory actions of Viscum album (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. Complement Ther Med 1997, 141-146.
71. Loewe-Mesch A, Kuehn JH, Borho K, Abel U, Bauer C, Gerhard I, Schneeweiss A, Sohn C, Strowitzki T, Hagens C. Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom - Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit. Forsch Komplementmed 2008, 15:22-30. 10.1159/000112860, 18334811.
72. Salzer G, Popp W. Die lokale Iscadorbehandlung der Pleurakarzinose. Krebs und Alternativmedizin II 1990, II:36-49. Berlin - Heidelberg, Springer-Verlag, Jungi WF, Senn H-J.
73. Böck D, Salzer G. Morphologischer Nachweis einer Wirksamkeit der Iscadorbehandlung maligner Pleuraergüsse und ihre klinischen Ergebnisse. Krebsgeschehen 1980, 12:49-53.
74. Enesel MB, Acalovschi I, Grosu V, Sbarcea A, Rusu C, Dobre A, Weiss T, Zarkovic K. Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Res 2005, 25:4583-4590.
75. Büssing A, Stumpf C, Tröger W, Schietzel M. Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts. Anticancer Res 2007, 27:2903-2910.
76. Hajto T. Immunomodulatory effects of Iscador: a Viscum album preparation. Oncology 1986, 43:51-65. 10.1159/000226420, 2433654.
77. Hajto T, Hostanska K. An investigation of the ability of Viscum album-activated granulocytes to regulate natural killer cells in vivo. Clin Trials J 1986, 23:345-358.
78. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 2004, 24:303-309.
79. Schleyerbach PW. Verlauf immunologischer Parameter bei Mammakarzinom unter Therapie mit Mistel-Extrakten: eine Anwendungsbeobachtung. PhD Thesis 2004, Eberhard-Karls-Universität zu Tübingen.
80. Kang SB. Efficacy of Mistletoe in the Management of Malignant Ascites. 2001, 35:27-28. Medizinische Woche Baden-Baden.
81. Gren A. Effects of Iscador preparations on the reactivity of mouse immune system. Neuroendocrinol Lett 2009, 30:153-157.
82. Jurin M, Zarkovic N, Borovic S, Kissel D. Viscum album L. preparation Isorel modifies the immune response in normal and in tumour-bearing mice. Anticancer Drugs 1997, 8:S27-S31.
83. Jurin M, Zarkovic N, Borovic S, Kissel D. Immunomodulation by the Viscum album L. preparation Isorel and its antitumorous effects. Grundlagen der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung 1996, 315-324. Stuttgart, Hippokrates Verlag GmbH, Scheer R, Becker H, Berg PA.
84. Rentea R, Lyon E, Hunter R. Biologic properties of Iscador: A Viscum album preperation. I. Hyperplasia of the thymic cortex and accelerated regeneration of hematopoietic cells following x-irradiation. Lab Invest 1981, 44:43-48.
85. Jurin M, Zarkovic N, Hrzenjak M, Ilic Z. Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology 1993, 50:393-398. 10.1159/000227217, 8233280.
86. Bloksma N, van Dijk H, Korst P, Willers J. Cellular and humoral adjuvant activity of a mistletoe extract. Immunobiol 1979, 156:309-319.
87. Lavelle EC, Grant G, Pusztai A, Pfüller U, O'Hagan DT. Mucosal immunogenicity of plant lectins in mice. Immunology 2000, 99:30-37. 10.1046/j.1365-2567.2000.00932.x, 2327126, 10651938.
88. Lavelle EC, Grant G, Pfüller U, Girbes T, Jimenez P, Pusztai A, Leavy O, O'Hagan DT, Mills KHG. Mucosal immunogenicity and adjuvanticity of plant lectins. Scand J Immunol 2000, 52:422.
89. Lavelle EC, Grant G, Pusztai A, Pfüller U, O'Hagan DT. The identification of plant lectins with mucosal adjuvant activity. Immunology 2001, 102:77-86. 10.1046/j.1365-2567.2001.01157.x, 1783150, 11168640.
90. Lavelle EC, Grant G, Pusztai A, Pfüller U, Leavy O, McNeela E, Mills KH, O'Hagan DT. Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2. Immunology 2002, 107:268-274. 10.1046/j.1365-2567.2002.01492.x, 1782787, 12383207.
91. Hajto T, Hostanska K, Weber K, Zinke H, Fischer J, Mengs U, Lentzen H, Saller R. Effect of a recombinant lectin, Viscum album Agglutinin on the secretion of Interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo. Nat Immun 1998, 16:34-46. 10.1159/000069428, 9789123.
92. Christen-Clottu O, Klocke P, Burger D, Straub R, Gerber V. Treatment of Clinically Diagnosed Equine Sarcoid with a Mistletoe Extract (Viscum album austriacus). J Vet Intern Med 2010, 24:1483-1489. 10.1111/j.1939-1676.2010.0597.x, 21039860.
93. Blostin R, Faivre C. Bénéfices du gui fermenté chez le chat après exérèse de fibrosarcome. Résultats d'une étude préliminaire. Phytotherapie 2008, 6:352-358.
94. Seifert G, Jesse P, Längler A, Reindl T, Lüth M, Lobitz S, Henze G, Prokop A, Lode HN. Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett 2008, 264:218-228. 10.1016/j.canlet.2008.01.036, 18314258.
95. Mengs U, Schwarz T, Bulitta M, Weber K. Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice. Anticancer Res 2000, 20:3565-3568.
96. Van Huyen JP, Delignat S, Bayry J, Kazatchkine MD, Bruneval P, Nicoletti A, Kaveri SV. Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett 2006, 243:32-37. 10.1016/j.canlet.2005.11.016, 16412563.
97. Raabe F, Storch H. Untersuchungen zur Therapie des Maus-Plasmozytoms mit Mistellektin I. Wiss Z Karl-Marx-Univ Leipz Math-Naturwiss R 1987, 36:535-543.
98. Seeger PG. Über die Wirkung von Mistelextrakten (Iscador und Plenosol). Erfahrungsheilkunde 1965, 14:149-174.
99. Franz H. Mistletoe lectins and their A and B chains. Oncology 1986, 43:23-34.
100. Zürner P. Sarkoidose nach Misteltherapie (Helixor)?. arznei-telegramm 1992, 5:51.
101. Grah C, Happel H, Vogt J. Die Behandlung der pulmonalen Sarkoidose nach dem Havelhöher Sarkoidose-Therapieprotokoll. Merkurstab 2008, 61:343-353.
102. Kümmell HC, Fricke L, Engelke P, Büssing A. Langzeitbeobachtung bei nicht-steroidaler Sarkoidosetherapie. Sarkoidose Nachrichten und Berichte 2003,
103. Harvey J, Colin-Jones DG. Mistletoe hepatitis. Br Med J 1981, 282:186-187.
104. Capernaros Z. The golden bough: the case for mistletoe. The European Journal of Herbal Medicin 1994, 1:17-21.
105. Abdel-Salam OM, Sleem AA, Shaffie NM. Effect of Viscum album on acute hepatic damage caused by carbon tetrachloride in rats. Turk J Med Sci 2010, 40:421-426., http://journals.tubitak.gov.tr/medical/issues/sag-10-40-3/sag-40-3-13-0803-12.pdf
106. Callard RE, Yates AJ. Immunology and mathematics: crossing the divide. Immunology 2005, 115:21-33. 10.1111/j.1365-2567.2005.02142.x, 1782120, 15819694.
107. Jameson SC. Maintaining the norm: T-cell homeostasis. Nat Rev Immunol 2002, 2:547-556.
108. Freitas AA, Rocha B. Population Biology of Lymphocytes: The Flight for Survival. Annu Rev Immunol 2000, 18:83-111. 10.1146/annurev.immunol.18.1.83, 10837053.
109. Gorter RW, Stein J, Stoss M, Linder M. Prospektive, longitudinale, Dosis-eskalierende, randomisierte Phase-I/II-Studie mit Iscador QuFrF und Iscador Qu Spezial mit HIV-Positiven, Krebspatienten und gesunden, nichtrauchenden Probanden. Forsch Komplementmed 1996, 3:169-175.
110. Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B. Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland. ArzneimForsch/DrugRes 2004, 54:456-466.
111. Friedel WE, Matthes H, Bock PR, Zänker KS. Systematic Evaluation of the Clinical Effects of Supportive Mistletoe Treatment within Chemo- and/or Radiotherapy Protocols and Long-Term Mistletoe Application in Nonmetastatic Colorectal Carcinoma: Multicenter, Controlled, Observational Cohort Study. J Soc Integr Oncol 2009, 7:137-145.
112. Temple L, Kawabata TT, Munson AE, White KL. Comparison of ELISA and Plaque-Forming Cell Assays for Measuring the Humoral Immune Response to SRBC in Rats and Mice Treated with Benzo[a]pyrene or Cyclophosphamide. Toxicol Sci 1993, 21:412-419.
113. Kim CJ, Berlin JA, Bugelski PJ, Haley P, Herzyk DJ. Combined analyses of heterogeneous immunotoxicology studies using functional T cell-dependent antibody response tests. Perspect Exp Clin Immunotoxicol 2007, 1:61-76.
114. Matthes B, Fritz P, Mürdter TE, Kröz M, von Laue H-B, Matthes H. Untersuchungen zu Immunreaktion und klinischem Outcome nach intraläsionaler Viscum-Applikation bei Kolonkarzinom. Fortschritte in der Misteltherapie Aktueller Stand der Forschung und klinischen Anwendung 2005, 491-498. Essen, KVC Verlag, Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H.
115. Gallimore A, Godkin A. Regulatory T cells and tumour immunity - observations in mice and men. Immunology 2007, 123:157-163. 10.1111/j.1365-2567.2007.02748.x, 2433304, 18067556.
116. Miller AM, Lundberg K, Özenci V, Banham AH, Hellström M, Egevad L, Pisa P. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006, 177:7398-7405.
117. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006, 108:804-811. 10.1182/blood-2006-02-002774, 16861339.
118. Hajto T, Hostanska K, Gabius H-J. Modulatory potency of the β-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in Rabbits and patients. Cancer Res 1989, 4803-4808.
119. Stoss M, Gorter R. Decrease of activated lymphocytes four and nine hours after a subcutaneous injection of a Viscum album L. extract in healthy volunteers. Nat Immun 1998, 16:185-197. 10.1159/000069445, 11061587.
120. Pfüller U, Mengs U, Schwarz T, Witthohn K, Pfüller K. Natürliche Mistellektine und das rekombinante Mistellektin im Vergleich - Biochemische und biologische Eigenschaften. Die Mistel in der Tumortherapie Grundlagenforschung und Klinik 2001, 3-13. Essen, KCV Verlag, Scheer R, Bauer R, Becker H, Berg PA, Fintelmann V.
121. Kuttan G, Kuttan R. Immunomodulatory activity of a peptide isolated from Viscum album extract (NSC 635089). Immunol Invest 1992, 21:285-296. 10.3109/08820139209069368, 1398778.
122. Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events. A randomized, controlled trial. Ann Intern Med 2006, 144:257-261.
123. Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N Engl J Med 1968, 279:678-679. 10.1056/NEJM196809262791304, 5670907.
124. Ioannidis JP, Evans SJ, Gøtzsche P, O'Neill RT, Altman DG, Schulz K, Moher D. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004, 141:781-788.
125. Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, Freedman SB, Goldsmith DI, Huang KA, Jones JK, McLeay R, Moore N, Stather RH, Trenque T, Troutman WG, vanPuijenbroek E, Williams F, Wise RP. Guidelines for Submitting Adverse Event Reports for Publication. Drug Saf 2007, 30:367-373. 10.2165/00002018-200730050-00001, 17472416.